Keywords: sanofi-synthelabo, 1st, qtr, below, consensus, although, french
Sanofi-Synthelabo 1st qtr below consensus
Article | 05 May 2003
Although French drugmaker Sanofi-Synthelabo posted a 13.4% increase on acomparable basis (5.6% reported) to 1.96 billion euros ($2.13 billion) in sales for the first ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
